Successful Treatment of Severe Atopic Dermatitis with Calcitriol and Paricalcitol in an 8-Year-Old Girl

Atopic dermatitis (AD) is a chronic inflammatory disease affecting children and adolescence. The traditional therapeutic options for AD, including emollients topically and immune modulatory agents systemically focusing on reducing skin inflammation and restoring the function of the epidermal barrier...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in pediatrics 2018-01, Vol.2018 (2018), p.1-5
Main Authors: Papadimitriou, D. T., Papadimitriou, Anastasios, Kleanthous, Kleanthis, Dermitzaki, Eleni, Alexopoulos, Alexis, Bothou, Christina, Mastorakos, George
Format: Article
Language:English
Subjects:
Age
Asthma
Case Report
Case reports
Clinical trials
Dendritic cells
Dermatitis
Dermatology
Diabetes
Eczema
Food allergies
Gene expression
Health care
Immune system
Immunology
Kidney diseases
Laboratories
Light therapy
Nephrology
Patients
Pediatrics
Skin
Teenagers
Vitamin D
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Atopic dermatitis (AD) is a chronic inflammatory disease affecting children and adolescence. The traditional therapeutic options for AD, including emollients topically and immune modulatory agents systemically focusing on reducing skin inflammation and restoring the function of the epidermal barrier, are proven ineffective in many cases. Several studies have linked vitamin D supplementation with either a decreased risk to develop AD or a clinical improvement of the symptoms of AD patients. In this report, we present a girl with severe AD who under adequate supplementation with cholecalciferol was treated with calcitriol and subsequently with paricalcitol. She had significant improvement—almost healing of her skin lesions within 2 months, a result sustained for more than 3 years now. Because of hypercalciuria as a side effect from calcitriol therapy, treatment was continued with paricalcitol, a vitamin D analogue used in secondary hyperparathyroidism in chronic kidney disease. Calcitriol therapy may be considered as a safe and efficacious treatment option for patients with severe AD, particularly for those with refractory AD, under monitoring for possible side effects. Treatment with paricalcitol resolves hypercalciuria, is safe, and should be further investigated as an alternative treatment of atopic dermatitis and possibly other diseases of autoimmune origin.
ISSN:2090-6803
2090-6811
DOI:10.1155/2018/9643543